Background Hyaluronic acid (HA) preparations are the most commonly used injectable fillers in esthetic medicine. In contrast to other injectable fillers with hyaluronidase, there is a tool available to reduce unwanted depots of this filler. Aims The aim of this paper is to give an overview on the present literature and in addition to give some recommendations for use based on the experience of the authors. Methods The overview is based on a literature search. Results There is some evidence from two smaller clinical trials that hyaluronidase will effectively decrease injected depots of HA. It has further been shown from case series and case reports that this reduction is clinically relevant. There is less evidence that hyaluronidase is also helpful in adverse reactions to HA-based fillers. Conclusions The reports suggest that the treatment is safe. However, adverse reactions to hyaluronidase such as allergic reactions have been reported. Patient should be informed about that before treatment.
Introduction
Hyaluronic acid (HA)-based fillers are the most commonly used fillers. 1, 2 With the increased involvement of sometimes inexperienced colleagues and nonphysicians like nurses and nonmedical practitioners as beauticians and natural healers ('Heilpraktiker') the risk of unwanted results rises. Unwanted results can mean overcorrection and asymmetries as well as adverse events to these injectable fillers. Although hyaluronic-based fillers are defined as temporary materials, they can last up to 12 months or longer. 3 Hyaluronidase destroys HA and gives the possibility to adjust overcorrection and asymmetries. Furthermore, hyaluronidase has also been suggested for the treatment of the rare adverse reactions to HA fillers as by hypothesis some of the HA might still be present in the skin which might be targeted by hyaluronidase.
The aim of this review is to present the evidence for the efficacy and safety of hyaluronidase and to discuss proposals of use for this indication.
Methodology
Literature was searched through MEDLINE for case reports or case series on hyaluronidase in the treatment of unwanted HA depots or adverse reactions to HA. The search comprised all literature until August 2008. The literature was analyzed separately for papers focusing on the treatment of overcorrections and adverse reactions toward HA.
Results
We were able to find several papers focusing on hyaluronidase as a corrective tool for HA in esthetic medicine.
Two experimental studies focused on the principals of efficacy of hyaluronidase in reducing depots of HA.
Experimental studies in humans
These two small prospective randomized studies (n = 12 and n = 8) were conducted sequentially by Varatian et al. 4 to determine the efficacy and dose dependency of hyaluronidase on NASHA gel implants ( Table 1 ). The first arm of the study was intended to compare the effects of injected hyaluronidase or saline on sites of previous NASHA gel injections. The second arm was designed to evaluate the dose-dependent effects of injected hyaluronidase on NASHA gel augmentation sites.
These are quite small experimental studies and, in fact, there was only a trend of a dose-response relationship. However, they demonstrate the efficacy of hyaluronidase in reducing small amounts of injected HA.
Efficacy of hyaluronidase in reducing unwanted depots of hyaluronic acid Most papers focus on the effect of hyaluronidase in reducing unwanted depots of HA (Table 2 ).
In addition to these case reports, one large case series can be found. The purpose of the case series comprising 155 patients was to describe the authors' experience with the treatment of periorbital hollows with HA (Restylane, Q-Med, Uppsala, Sweden). 5 For some reason, 11% of patients (n = 17) received hyaluronidase to reduce contour irregularities. The typical dose used was 0.3-1.0 mL of a 15 U ⁄ mL solution. The authors report incomplete response to the attempts to decrease the residual HA gel by using hyaluronidase injections when the unwanted effect was a doughy edema.
In addition, two papers could be found that focused on the reduction of HA depots in patients with probable vascular reactions (Table 3 ).
Hyaluronidase to reduce the effects of adverse reactions to hyaluronic acid preparations Three papers could be found focusing on the effect of hyaluronidase on the treatment of adverse reactions to HA ( Table 4) .
Safety of hyaluronidase
Adverse reactions to hyaluronidase are rare. In his case series, e.g., Sopokar et al. 6 reported only in 2 of 97 treated patients a temporary postinjection pruritus. However, allergic and even a few anaphylactic reactions have been associated with hyaluronidase. Most reports are based on ophthalmological or other nonesthetic interventions. [7] [8] [9] [10] In addition, a couple of reports after the use of ovine as well as bovine hyaluronidase for esthetic indications can be found 11 (Becker-Wegerich 2009, personal communication). In both cases, edema developed rapidly after the injection. The edema was controlled by steroid injections.
Available hyaluronidase preparations in Europe (Table 5 ) Most available hyaluronidase products use hyaluronidase of bovine origin. In addition, hyaluronidase of ovine origin exists.
, Riemser Arzneimittel AG, Greifswald -Insel Riems, Germany) was developed as a spreading or diffusing substance to increase the permeability of connective tissue through the hydrolysis of HA. The enzyme is extracted from bovine testes. The bovine testes used are obtained from New Zealand from a source which is recognized as being completely BSE (Bovine Spongiform Encephalopathy) free.
Hyaluronidase is an enzyme that breaks down HA (hyaluronan) by cleaving glycosidic bonds of HA and, to some extent, other acid mucopolysaccharides of the connective tissue. 12 The physiologic role of hyaluronidase is seen in stimulating angiogenesis by defragmenting HA. The fibrotic healing of adult and late gestational wounds correlates with an increased hyaluronidase activity and a removal of hyaluronan. 13 Further consideration see hyaluronidase as a regulatory agent in HA homeostasis and metabolism. 14 Hyaluronidase cannot cross the blood-brain barrier. 15 The clinical use and therapeutic benefits of hyaluronidase began in the early 1950s. In 1952, Breu discovered that the enzyme is capable of spreading dyes or other substances in tissue and of significantly increasing the permeability of skin and connective tissue via the breakdown of HA. The enzyme hyaluronidase is a ''hydrolase'' with a molecular weight of approximately 60 000 Da. 16 Hylase Ò ''Dessau'' comes as a white powder which needs to be diluted with saline before injection. The smallest vial available contains 150 U. The product contains no preservatives. The product is manufactured during a sophisticated multistep procedure established and patented in Germany for many decades. It is a highly purified bovine protein extract with a low allergic or sensitizing potential. Hylase Ò ''Dessau'' must be stored at cool temperatures (2-8°C). These conditions guarantee the constant quality of the product over a long period. Additional tests have shown the stability of the product at controlled room temperature (25°C ± 2°C ⁄ 60% relative humidity [RH] ± 5% RH) over a period of at most 12 months (Supplementary Protection Certificate).
Other hyaluronidase preparations
In the literature, several other hyaluronidase preparations were used. In the earlier papers, hyaluronidase derived from Lee Pharmacy, Inc., Fort Smith, AZ, USA; 50 U ⁄ cc. 17 Hirsch et al. 18, 19 20 
Practical consideration
Although there are no large randomized-controlled trials on the efficacy of hyaluronidase in reducing unwanted depots of HA, based on the reviewed literature and based on the personal experience of the authors some practical considerations can be given.
In the case of unwanted depots of HA, the following steps should be performed:
• Inform the patient that hyaluronidase is not licensed so far for the treatment of unwanted HA depots.
• Inform also the patient that in rare cases, adverse reactions to the hyaluronidase have been known. Do NOT skin test. The allergic reactions are quite rare and cannot totally be excluded by skin test.
• Do NOT treat patients with a known allergy to bovine protein if the hyaluronidase used derives from bovine material.
• Dilute the hyaluronidase (150 U vial) with 0.9% saline (1 mL) and inject the mixture in the HA depots. There is NO evidence that the addition of lidocaine or epinephrine is helpful. The volume used depends on the quantity of injected HA. Usually 0.05-0.1 mL per injection point (7.5-15 U) is sufficient. Inject slowly.
• Choose the needle size according to the location and the size of the depot. Use a 30-gauge (0.3 · 13 mm) needle for more superficial nodules and a 27-gauge (0.4 · 20 mm) or a 26-gauge (0.45 · 10mm) needle for deeper nodules.
• Make sure to inject in the HA depot; in cases of very superficial HA depots, inject just beneath the depot.
• For nodules exclusively due to HA, some patients notice an obvious decrease or a disappearance of the nodule within 24-48 h. For nodules of unknown cause, an obvious reduction of inflammation and size has been induced in some patients. Usually, an apparent regression is noticeable within 24-48 h; however, in inflamed nodules a complete disappearance may take longer. Therefore, a control visit should be scheduled about 2 weeks after the injection.
• If the nodule is very inflamed and an abscess may be likely an adjuvant systemic antibiotic treatment, e.g., with ciprofloxacine or levofloxacine 250 mg once daily, should be initiated as hyaluronidase may act as the spreading factor.
• For the same reason (potentially increased spreading) hyaluronidase should not be injected in an area that has been treated with botulinum toxin A in the last 48 h.
• If an immediate reaction occurs treat accordingly to the prevailing symptoms. As for every allergic reaction, an allergy pass card should be issued. Furthermore, an allergological workup is recommended.
Conclusions
HA preparations are the most used injectable fillers on the market. As the esthetic market is growing, more and more patients will be treated with HA. This will lead to more patients with a relative or absolute overcorrection and patients who suffer from immediate or long-term adverse events from these products. A product like hyaluronidase can therefore be considered as a rescuemedication which can help reverse overcorrection or some more severe complications. There is some evidence from two smaller clinical trials that hyaluronidase will effectively decrease injected depots of HA. There is further evidence from case series and case reports that this reduction is clinically relevant. There is very little evidence that hyaluronidase is also helpful in adverse reactions to HA-based fillers.
The reports suggest that the treatment is safe. However, adverse reactions, as allergic reactions, to hyaluronidase of bovine or ovine origin have been reported. Patients should be informed about that before treatment.
Colleagues should be instructed about this very beneficial tool and how it should be used.
